A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study ofSubcutaneous MOA-728 for the Treatment of Opioid-Induced ConstipationEstudio multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos
Ontology highlight
ABSTRACT: Primary: To evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with nonmalignant pain who have opioid-induced constipation.
Primary endpoints: Two coprimary efficacy endpoints are:1. the proportion of subjects having a RFBM within 4 hours of the first dose administration, and 2. the percentage of injections resulting in any RFBM within 4 hours during the double-blind period.
DISEASE(S): Opioid-induced Constipation In Subjects With Non-malignant Paintratamiento Del Estreñimiento Inducido Por Opiáceos En Sujetos Con Dolor De Origen No Maligno,Constipation
PROVIDER: 2525287 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA